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ABSTRACT: Background. The purpose of this study was to determine if
there are differences in biomarker modulation and epidermal growth
factor receptor (EGFR) degradation between the tumor and the normal
mucosa after treatment with an EGFR inhibitor, erlotinib, in head and
neck cancer.
Methods. Patients with primary oral cavity squamous cell cancers
received a course of erlotinib, 150 mg every day for 7 days before
surgical resection. Tumor and normal mucosa biopsies were obtained
both pre-erlotinib and post-erlotinib. Changes in known markers of EGFR
activity (phospho, AKT, STAT3) were measured by immunoblotting,
whereas changes in tissue distribution were analyzed by
immunohistochemical analysis.
Results. Twelve patients were enrolled; 7 had evaluable paired tumors
and normal mucosa biopsies pretreatment and posttreatment.
Expression of EGFR was higher in tumors compared to the normal
mucosa (p ¼ .005). Erlotinib administration was associated with marked
inhibition of phosphorylated epidermal growth factor receptor (pEGFR)
and reduction in total EGFR protein (p ¼ .004, p ¼ .007) in tumors,
whereas there was heterogeneity in EGFR inhibition in the normal
mucosa (p ¼ .10 [pEGFR], and p ¼ .07 [EGFR]). Reduced levels of pSrc
and pSTAT3 and enhanced p27 levels were noted in tumors after
erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor
cells after prolonged treatment with erlotinib.
Conclusion. Our results show that EGFR inhibition by erlotinib led to a
marked reduction in EGFR protein levels in patients. Differential effects
of erlotinib on tumors compared to the normal mucosa suggest there
may be individual patient heterogeneity. These preliminary data suggest
EGFR degradation should be further analyzed as a potential biomarker in
selecting patients likely to benefit from EGFR inhibitors. VC 2012 Wiley
Periodicals, Inc. Head Neck 35: 1323–1330, 2013
KEY WORDS: erlotinib, degradation, primary oral cavity cancer,
normal mucosa, biomarker
INTRODUCTION
Epidermal growth factor receptor (EGFR) represents a
promising molecular target that regulates both the growth
and potential spread of squamous cell carcinomas of the
head and neck.1–4 Although 85% to 100% of head and
neck squamous cell carcinomas are noted to have overex-
pression of EGFR, the clinical response rate produced by
an EGFR inhibitor alone is only 10% to 15%. There has
been no direct correlation noted between EGFR overex-
pression and clinical response.5–7 Other molecular predic-
tors of response are needed to select patients most likely
to benefit from targeted therapies.8 Unfortunately,
although EGFR gene mutations predict response to EGFR
tyrosine kinase inhibitors, such as erlotinib,9–11 in lung
adenocarcinoma, there is no evidence of activating EGFR
mutations in head and neck cancer.12–15 Similarly, neither
EGFR gene amplification, polysomy, nor truncation
(EGFRvIII) predicts response to EGFR inhibitors in
patients with head and neck cancer (although they do
carry prognostic value).12,16–18
Phosphorylation is a key factor in predicting response
to EGFR inhibitors in preclinical studies.19–21 However,
there is increasing preclinical evidence that EGFR degra-
dation could play an even greater role in predicting
response.19,22–26 For instance, knockdown of EGFR with
siRNA can induce autophagic cell death independent of
receptor tyrosine kinase activity.27 We have also found
that EGFR degradation is an important mechanism that
regulates chemotherapy induced cytotoxicity.24,26 These
findings suggest that EGFR degradation may be more
effective in producing cytotoxicity of EGFR driven
tumors than inhibition of EGFR activity alone.
We hypothesized that inhibition of EGFR signaling
and/or EGFR degradation may be an important predictor
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of response. A first step in testing this hypothesis, and
the primary purpose of this pilot study, was to determine
if erlotinib could produce inhibition of downstream
EGFR signaling and EGFR degradation in patients with
head and neck cancer. A secondary purpose of this study
was to determine if there were differences in EGFR lev-
els as well as other possible biomarkers between tumor
and the normal mucosa. Acute and late pharyngeal toxic-
ities are the major cause of morbidity in patients with
head and neck treated with concurrent chemoradia-
tion.28,29 Although targeted therapies are anticipated to
have less toxicity compared to chemotherapy due to
selective cell kill, the differential effects of EGFR inhibi-
tion in tumor compared to normal tissue have not yet
been studied.
MATERIALS AND METHODS
Patient characteristics
Patients eligible for this study had histologically con-
firmed head and neck squamous cell carcinoma (HNSCC)
that required primary surgical resection. Eligibility criteria
included age greater than 18 years, Zubrod score of 2,
and ability to provide written consent. Exclusion criteria
included prior EGFR antibody or tyrosine kinase inhibitor
therapy, known malabsorption syndrome or any other con-
dition that would impair absorption of the study drug, and
concurrent serious infections or coexisting medical prob-
lems that would limit study compliance. Acceptable hema-
tologic, renal, and liver function was required. Pregnant
and lactating women were excluded from this study.
Treatment plan
All patients underwent a physical examination, medical
history, laboratory evaluation, and CT imaging at baseline.
Toxicities were graded using the National Cancer Institute
common toxicity criteria version 3.0. Patients were
instructed to start oral erlotinib 150 mg prescribed orally
every day, 7 days before surgical resection. The final erloti-
nib dose was taken at least 8 hours before surgical resec-
tion. In the event of a grade 2 or greater diarrhea or skin
rash, the drug was withheld until resolution and then
restarted at 100 mg prescribed orally every day. The num-
bers of pills the patient had taken and the time at which the
final dose was taken were recorded at the follow-up visit.
Tissue biopsies
Baseline tissue core biopsies of a minimum of 3  3 
3mm sample from both the tumor and the uninvolved con-
tralateral oral mucosa were obtained. These samples were
collected in ice-cold saline containing a cocktail of protease
(Roche Diagnostic, Indianapolis, IN) and phosphatase
inhibitors (Sigma, St. Louis, MO). After a 7-day course of
EGFR tyrosine kinase inhibitor erlotinib, repeat core tumor
and contralateral normal-appearing mucosa biopsies were
obtained at the time of surgical resection in similar regions
as the initial baseline biopsies. Biopsies were divided into 2
parts; the first was used in high-throughput and traditional
immunoblot analysis, and the second was fixed in formalin
for immunohistochemical analysis. EGFR phosphorylation,
total EGFR, and associated downstream signaling pathways
were analyzed by immunoblotting and immunostaining as
described below. All tumor and normal tissue biopsy speci-
mens were also reviewed by an experienced head and neck
pathologist (N.D’S.).
High-throughput immunoblotting
Tissue samples were lysed in the sample extraction
buffer and immunoblotting was performed using a protocol
previously described.30 A total of 100 lg protein was sub-
jected to electrophoresis on a 2D 4% to 12% bis-tris precast
gel (Invitrogen, Carlsbad, CA) and transferred onto a poly-
vinylidene fluoride membrane. A Miniblotter 28 dual sys-
tem (Immunetics, Cambridge, MA) was used to probe all
the antibodies). After incubating the membrane with differ-
ent antibodies overnight, membranes were washed for 30
minutes with TRIS-buffered saline–Tween-20 (TBS-T)
and probed with horseradish peroxidase conjugated immu-
noglobulin G (Cell Signaling Technology, Beverly, MA),
diluted 1:10,000 in TBS-T for 1 hour at room temperature;
the antigen-antibody complexes were visualized by
enhanced chemiluminescence (ECL-Plus; Amersham Bio-
sciences, Piscataway, NJ). For quantification of relative
protein levels, immunoblot films were scanned and ana-
lyzed using National Institutes of Health ImageJ software.
Unless otherwise indicated, the relative protein levels
shown represent a comparison to untreated controls.
Immunohistochemistry
Immunohistochemical staining was performed as
described previously.30 The 4- to 5-lm sections were pre-
pared using a microtome and placed onto slides. Sections
were subjected to heat-mediated antigen retrieval in citrate
buffer (10 mM citric acid, pH 6.0). After blocking with
5% donkey serum for 1 hour at room temperature, sections
were incubated with primary antibody overnight at 4C in
a humidified chamber. After 3 phosphate-buffered saline
washes, horseradish peroxidase-conjugated second antibody
was used to form a complex with the primary antibody,
and unbound antibodies were removed by washing in
TBS-T 3 times. Finally, this complex was visualized using
the ECL Peroxidase Substrate Kit (Vector Labs, Burlin-
game, CA), and sections were counterstained with hema-
toxylin, washed, and mounted. Images were acquired using
a DP70 camera fitted on an Olympus 1X-71 microscope.
Apoptotic cell death was assessed using ApopTag Peroxi-
dase In Situ Apoptosis Detection Kit (Milipore, Billerica,
MA). Slides were evaluated by 2 investigators, and 3 areas
from each section were analyzed.
Statistics
Analysis was performed using SPSS for Windows sta-
tistical software package (SPSS version 11; SPSS, Chi-
cago, IL). A pairwise 2-tailed t test was used to evaluate
immunohistochemistry results pretreatment and posttreat-
ment for paired biopsies. The results of statistical tests
were considered statistically significant at p < .05.
RESULTS
Patient characteristics
Twelve patients were enrolled in the study. Baseline
characteristics are shown in Table 1. Median age was 72
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years (range, 21–86 years). There were 7 women and 5
men. Median Zubrod score was 0 (range, 0–1). Primary
oral cavity tumors were included; floor of mouth (n ¼ 3),
tongue (n ¼ 8), and retromolar trigone (n ¼ 1). The major-
ity (7 of 12) of the tumors were American Joint Committee
on Cancer T3 or T4 classification. Six patients also had
nodal disease. Smoking status was available in all patients:
current smokers (n ¼ 5), former smokers (n ¼ 4), and never
smokers (n ¼ 3). All 12 patients had pretreatment tumor
biopsies. One patient underwent repeat positron emission
tomography scan after enrollment and was noted to have
newly diagnosed metastatic lung disease and therefore did
not undergo surgical resection as planned. Tumor speci-
mens were nonevaluable due to technical issues in 2 cases.
In 4 cases, baseline normal tissue biopsies at postprocess-
ing were nonevaluable due to the small size of the biopsies.
Therefore, a total of 9 paired tumors and 7 paired normal
tissue biopsies were available for analysis.
Pathologic and immunohistochemistry analyses
An initial qualitative analysis of the normal oral mucosa
versus tumor cells was obtained using hematoxylin-eosin
stain, PAN-cytokeratin, and Ki-67 staining (Figure 1).
PAN-cytokeratin and hematoxylin-eosin staining were used
to confirm the presence of tumor cells. After erlotinib
treatment, there was a decrease in PAN-cytokeratin stain-
ing along with altered cellular architecture. Likewise,
Ki67, a marker for proliferation, was markedly suppressed
by erlotinib in the tumor, whereas minimal effects were
noted in the normal mucosa. Additional qualitative analysis
using immunohistochemistry of EGFR confirmed strong
staining in the pretreatment tumor biopsies. There was a
dramatic reduction of EGFR staining after a 7-day course
of erlotinib. Normal mucosa biopsies showed a more vari-
able response and did not consistently demonstrate a simi-
lar decrease in EGFR staining (Figure 1 and 2). We also
wanted to determine if erlotinib could cause tumor cell
death after a 1-week course of treatment. We noted a mod-
est increase in the number of apoptotic cells upon immuno-
staining in the tumor tissue posttreatment.
Immunoblotting analyses
In order to quantify the effects of erlotinib treatment on
both the tumor and normal tissue, we performed immuno-
blotting for both the paired tumor (n ¼ 9) and normal tis-
sue (n ¼ 7) biopsies. Erlotinib treatment led to a marked
decrease of both phosphorylated epidermal growth factor
receptor (pEGFR; both the Y845 site and the Y1173 site)
and total EGFR protein (p ¼ .004 and p ¼ .007, respec-
tively) in the tumor biopsies (Figure 2A and B). In con-
trast, EGFR inhibition in the normal mucosa was more
heterogeneous showing a weak and nonsignificant
decreasing trend after erlotinib for both pEGFR (p ¼ .10)
and total EGFR protein (p ¼ .07; Figure 2C and D). We
also analyzed the effects of erlotinib on other key down-
stream signaling molecules of EGFR. We compared pre-
erlotinib and post-erlotinib matched tumor samples and
found that levels of pSrc, pSTAT3, pERK, and pAKT
were significantly reduced after treatment with erlotinib.
Total Src, STAT, ERK, and AKT were relatively
unchanged, demonstrating that, among key signaling mol-
ecules, EGFR was specifically decreased. Our preclinical
studies support that this is likely due to receptor degrada-
tion after erlotinib treatment (Figure 3).
In addition to assessing the effect of 7 days of erlotinib
treatment on kinases involved in growth and invasion, we
also assessed the cell cycle checkpoint protein p27 (Fig-
ures 2A and 3B). As expected, we found a significant
increase in p27 levels. In preclinical studies, it has been
shown that this is associated with cell accumulation in
G1-phase.
31 We also assessed the effect of erlotinib treat-
ment on B-cell CLL/lymphoma-2 (Bcl2) levels, which is
a known inhibitor of apoptotic cell death. We saw a
decrease in Bcl2 levels in the patient tumor specimens,
whereas in the normal tissue (not shown) or normal cells
we observed a modest increase. Finally, we evaluated
housekeeping proteins glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) and HSP90, neither of which
showed any significant change in levels in response to
erlotinib treatment (Figures 2 and 3). These key findings
support the use of multiplex immunoblotting as a method
for assessing multiple signal transduction molecules in
prospective clinical studies.
Single versus daily exposure to erlotinib in cultured cells
As erlotinib has chiefly been reported to block EGFR
phosphorylation rather than cause EGFR degradation, we
conducted cell culture studies to better understand these
clinical observations. Whereas a single exposure to erloti-
nib only inhibited EGFR phosphorylation, continued ex-
posure led to EGFR degradation and p27 accumulation
(Figure 3A). We also determined the effect of EGFR
inactivation on the downstream molecules shown in Fig-
ure 1B in 2 tumors and 2 normal cell lines. Similar to
patient data (Figure 2B), both of the tumor cell lines
showed a decrease in total EGFR levels as well as down-
stream signaling molecules. Normal fibroblasts and the
MRC-5 normal cell lines were also treated with erlotinib
for comparison (Figure 3E and F), which caused an
increase in Bcl2. This suggests that erlotinib might pro-
tect normal cells from apoptosis. Other key signaling
molecules were minimally altered.
TABLE 1. Baseline characteristics.
Characteristic
No. of patients
(N¼12)
Median age, 72 y (range, 2–61 y)
Male/female 5/7
Primary tumor site: oral cavity
Floor of mouth 3
Tongue 8
Retromolar trigone 1
AJCC tumor stage
I 2
II 1
III 3
IVA 5
IVC 1
Smoking history
Never smokers 3
Former smokers 4
Current smokers 5
Abbreviation: AJCC, American Joint Committee on Cancer.
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DISCUSSION
This pilot study confirms that pEGFR, total EGFR, and
key downstream signaling molecules are consistently
decreased in head and neck tumors after a 1-week course
of the tyrosine kinase EGFR inhibitor, erlotinib. In con-
trast, there was substantial heterogeneity in the effects of
erlotinib on the normal mucosa in patients. The findings
of a decrease in total EGFR in patients with head and
neck cancer is novel and is consistent with our prior pre-
clinical findings.19 Our data suggest a potential rationale
for using molecular biomarkers to permit the selection of
patients most likely to realize a therapeutic index with
erlotinib in head and neck tumors. Given the small
patient numbers, a larger prospective clinical trial is cur-
rently being conducted to confirm the finding of EGFR
degradation as a potential important molecular biomarker
of cytotoxicity.
FIGURE 1. Assessment of epidermal growth factor receptor (EGFR) after erlotinib therapy in patients with head and neck cancer. Pre-erlotinib and
post-erlotinib treated (oral, 150 mg/day  7 days) tumor specimens were collected and analyzed for EGFR and other downstream molecules. In
patient #1, EGFR staining in the tumor (shown inside the dotted line) appears reduced in the posttreatment biopsy compared to the pretreatment
biopsy with unaffected staining noted in the adjacent normal gland. Tumor cells were confirmed by PAN-cytokeratin and hematoxylin-eosin
staining. In the posttreatment tumor biopsy, there is a decrease in Ki67 staining and pan-cytokeratin staining along with altered cellular
architecture as shown by hematoxylin-eosin stain. Sections were stained with ApopTag to assess if the mode of cell death was apoptosis.
Increased ApopTag staining is seen in the posttreatment tumor biopsy compared to the pretreatment and normal biopsy specimens indicating an
increase in apoptotic tumor cells after treatment. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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The current standard of care for good performance
patients with locally advanced head and neck cancer is
chemoradiation, concurrent cetuximab and radiation, or
primary surgery followed by adjuvant chemo-
radiation.32–34 A phase III randomized study showed that
there is no further improvement in disease-free or overall
survival from the addition of cetuximab in unselected
patients receiving concurrent chemoradiation with cispla-
tin.35 After a median follow-up of 2.4 years, there was no
difference in progression-free survival or 2-year overall
survival; 82.6% in patients receiving cetuximab and
79.7% in patients treated without the monoclonal anti-
body. In this trial, patients in the cetuximab arm had a
significantly higher incidence of severe (grade 3/4) muco-
sitis (43% vs 33%; p ¼ .004), in-field skin reactions
(25% vs 15%; p < .001), and out-of-field skin reactions
(19% vs 1%; p < .001). Late toxicity (>90 days), includ-
ing persistent dysphagia, occurred in a similar proportion
of patients in each treatment arm.35 Thus, it is unclear
which patients may benefit from the addition of EGFR
inhibitors to concurrent chemoradiation. Identification of
potential molecular biomarkers predictive of response
would be beneficial in selecting patients most likely to
respond to targeted therapies not only in regard to effi-
cacy but, potentially, in reducing normal tissue toxicity.
Such information might also be useful in the national
ongoing randomized phase III trial for patients with
favorable human papillomavirus-16–related oropharyngeal
cancer to determine whether EGFR inhibition with radia-
tion and weekly cetuximab is more efficacious than con-
current chemotherapy and radiation and also to confirm if
the morbidity is reduced.
Our findings suggest that EGFR degradation is a poten-
tial biomarker of response to targeted therapies. Degrada-
tion seems to be an important mechanism of cell death in
head and neck tumors that are dependent on EGFR
FIGURE 2. Analysis of changes in epidermal growth factor receptor (EGFR) levels and associated signaling mediators using multi-immunoblotting
after erlotinib therapy. (A) Pretreatment and posttreatment specimens were resolved on 2D gels and multi-immunoblotting was carried out. Protein
samples were probed with various antibodies against EGFR signaling mediators and several constitutively expressed proteins. Changes in signaling
mediators pre-erlotinib and post-erlotinib treatment were analyzed by comparing film exposures showing similar levels of constitutively expressed
proteins. Representative pre-erlotinib and post-erlotinib treatment multiblots (averaged data obtained from 3 patients) showed not only a decrease
in EGFR and pY845EGFR as observed in traditional immunoblotting, but various other downstream and associated signaling mediators of EGFR
were also analyzed simultaneously on a single platform. (B) Signaling mediators of EGFR pathway including downstream mediators were resolved,
and changes after erlotinib treatment (normalizing with glyceraldehyde 3-phosphate dehydrogenase [GAPDH]) are plotted, with reduced levels of
pSTAT3, pAKT, pERK, BCL-2, and increase in p27. (C) The effect of erlotinib treatment on EGFR expression in tumor and normal tissue in 4
representative patient samples. The changes in EGFR levels in the tumor and normal tissue were quantified, and the median EGFR levels relative to
pretreatment are expressed in (D) obtained from 9 paired tumor biopsies and 7 paired normal mucosa biopsies.
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signaling. As EGFR plays a role in DNA repair,30 EGFR
degradation may decrease the ability of cells to repair
damaged DNA, leading, therefore, to increased cytotoxic-
ity. We have demonstrated that decreased EGFR levels
after gemcitabine26 or cisplatin24 chemotherapy correlate
with decreased clonogenic survival. Furthermore, inhibi-
ting EGFR degradation by treating with lysosomal or pro-
teosomal inhibitors26 or by introducing mutations that
prevent c-Cbl from binding to EGFR,24 a key step in pro-
teosomal degradation, decreases chemotherapy induced
cytotoxicity.24 Cetuximab and erlotinib can also cause
EGFR degradation.36 EGFR degradation occurs along a
pathway similar to EGF-induced receptor downregulation.
The loss of EGFR can lead to the downregulation of
pAKT causing apoptosis. Our in vitro studies presented
in the current study confirm that EGFR degradation does
not tend to occur after a single administration of erlotinib,
which likely explains why degradation has not been
detected by studies that have focused on shorter exposure
periods.
Other potential molecular markers predictive of
response to EGFR-targeted therapies have also been stud-
ied.37–39 A pilot study in patients with HNSCC used neo-
adjuvant erlotinib for 3 weeks before surgical resection
FIGURE 3. Effects of single versus daily exposure to erlotinib on epidermal growth factor receptor (EGFR) expression and downstream signaling in
head and neck cancer cell lines. (A) UMSCC1 cells were treated with erlotinib (3 lM) either once or daily for 7 days. Cells were harvested, and
immunoblotting was performed to detect EGFR, pY845EGFR, p27, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (B) The effects of a 1-
week treatment with erlotinib on EGFR and other signaling molecules that were assessed in the patients’ samples were analyzed in UMSCC1 and
UMSCC11B cells. A decrease in total EGFR levels was observed in both cell lines. Treatment with erlotinib did not alter human epidermal receptor
2 (HER2) levels. Erlotinib treatment led to a decrease in pERK1/2, pAKT, and pSrc levels, and p27 accumulation in both cell lines. (C–F) The change
upon erlotinib treatment (normalizing with GAPDH) are shown for UMSCC1 and UMSC11B (C and D) as well as normal fibroblasts and the MRC5
normal cell line (E and F). Similar downstream effects were noted in the cancer cell lines as were seen in the patient tumor samples. Normal cell
lines showed an increase in the Bcl2 levels after erlotinib treatment.
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and noted a clinical response in 9 of 31 patients. Erlotinib
led to a significant reduction in extracellular signal regu-
lated kinases-1/2 in patients. Their results suggested that
baseline p21(waf) expression seemed to positively corre-
late with clinical response to erlotinib, whereas the EGFR
copy number did not.37 Additional biomarker studies have
analyzed the effects of erlotinib on EGFR-related signal-
ing in 7 paired tumor biopsies and 20 paired skin biopsies
from patients with recurrent or metastatic HNSCC. Of 25
patients enrolled, 2 patients were noted to have a
response; complete response and a partial response,
respectively. There was a trend for patients with more
severe skin toxicity to have a more pronounced antitumor
effect. Erlotinib therapy was associated with a decrease in
pEGFR expression in 4 of 6 tumors (66%) and 7 of 20
sampled skin biopsies (35%). P-27 upregulation after
erlotinib therapy was also noted in 11 of 19 evaluable
skin biopsies (59%).40 In a similar study, the effect of
gefitinib on EGFR signaling was assessed after a 1-week
course of gefitinib before combined gefitinib, paclitaxel,
and radiation in locally advanced head and neck cancer.41
Tumor biopsies were obtained before and 7 days after
gefitinib. The main focus of this study was to assess the
baseline membrane and nuclear EGFR and changes in the
molecular profile using immunohistochemical analysis to
predict the response to gefitinib combined with
chemoradiation.
In this study, although the nuclear EGFR levels were
significantly reduced in 3 of 7 patients, the authors did
not find any correlation between molecular changes and
final response to treatment.
To date, there are no reliable molecular markers identi-
fied that correlate with the response to EGFR inhibitors
in head and neck cancers.
Clinical data continue to support EGFR as a key molec-
ular target in head and neck cancer. In this study, we
were able to confirm that erlotinib caused a marked
reduction in EGFR protein levels consistent with our prior
preclinical studies. We provided preliminary clinical data
suggesting that the normal mucosa does not seem to be as
consistently affected by EGFR-targeted therapy as the tu-
mor, suggesting a differential effect of erlotinib in tumors
compared to the normal mucosa. Therefore, we are cur-
rently conducting a larger prospective clinical trial to
evaluate whether EGFR degradation after EGFR-targeted
therapy is a potential molecular biomarker of clinical
response in patients receiving cetuximab and radiation in
patients with human papillomavirus–positive primary oro-
pharyngeal cancer.
REFERENCES
1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of
head and neck cancer. Nat Rev Cancer 2011;11:9–22.
2. Perez–Ordo~nez B, Beauchemin M, Jordan RC. Molecular biology of squa-
mous cell carcinoma of the head and neck. J Clin Pathol 2006;59:
445–453.
3. O-charoenrat P, Rhys–Evans PH, Modjtahedi H, Eccles SA. The role of c-
erbB receptors and ligands in head and neck squamous cell carcinoma.
Oral Oncol 2002;38:627–640.
4. Khademi B, Shirazi FM, Vasei M, et al. The expression of p53, c-erbB-1
and c-erbB-2 molecules and their correlation with prognostic markers in
patients with head and neck tumors. Cancer Lett 2002;184:223–230.
5. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a tar-
get in cancer therapy: understanding the role of receptor expression and
other molecular determinants that could influence the response to anti-
EGFR drugs. Eur J Cancer 2003;39:1348–1354.
6. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epi-
dermal growth factor receptor (EGFR) status in primary colorectal tumors
does not correlate with EGFR expression in related metastatic sites: impli-
cations for treatment with EGFR-targeted monoclonal antibodies. J Clin
Oncol 2004;22:4772–4778.
7. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor
receptor expression as a predictive factor for response to gefitinib (‘Iressa’,
ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91:208–212.
8. Brugger W, Triller N, Blasinska–Morawiec M, et al. Prospective molecu-
lar marker analyses of EGFR and KRAS from a randomized, placebo-con-
trolled study of erlotinib maintenance therapy in advanced non-small-cell
lung cancer. J Clin Oncol 2011;29:4113–4120.
9. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features
associated with epidermal growth factor receptor gene mutations in lung
cancers. J Natl Cancer Inst 2005;97:339–346.
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst 2005;97:643–655.
11. Paez JG, J€anne PA, Lee JC, et al. EGFR mutations in lung cancer: correla-
tion with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
12. Szabo B, Nelhubel GA, Karpati A, et al. Clinical significance of genetic
alterations and expression of epidermal growth factor receptor (EGFR) in
head and neck squamous cell carcinomas. Oral Oncol 2011;47:487–496.
13. Sheikh Ali MA, Gunduz M, Nagatsuka H, et al. Expression and mutation
analysis of epidermal growth factor receptor in head and neck squamous
cell carcinoma. Cancer Sci 2008;99:1589–1594.
14. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in
squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:
2879–2882.
15. Lemos–Gonzalez Y, Paez de la Cadena MP, Rodrı´guez–Berrocal FJ,
Rodrı´guez–Pi~neiro AM, Pallas E, Valverde D. Absence of activating muta-
tions in the EGFR kinase domain in Spanish head and neck cancer
patients. Tumour Biol 2007;28:273–279.
16. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor
receptor gene copy number is associated with poor prognosis in head and
neck squamous cell carcinomas. J Clin Oncol 2006;24:4170–4176.
17. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor
receptor (EGFRvIII) contributes to head and neck cancer growth and re-
sistance to EGFR targeting. Clin Cancer Res 2006;12:5064–5073.
18. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final
overall survival results from a phase III, randomized, open-label, first-line
study of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin
Oncol 2011;29:2866–2874.
19. Feng FY, Lopez CA, Normolle DP, et al. Effect of epidermal growth factor
receptor inhibitor class in the treatment of head and neck cancer with con-
current radiochemotherapy in vivo. Clin Cancer Res 2007;13:2512–2518.
20. Nyati MK, Lawrence TS. Hitting the target: measuring EGFR response to
tyrosine kinase inhibitors. Cancer Biol Ther 2005;4:1387–1388.
21. Nyati MK, Maheshwari D, Hanasoge S, et al. Radiosensitization by pan
ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004;10:
691–700.
22. Ray D, Ahsan A, Helman A, et al. Regulation of EGFR protein stability by
the HECT-type ubiquitin ligase SMURF2. Neoplasia 2011;13:570–578.
23. Argiris A, Duffy AG, Kummar S, et al. Early tumor progression associated
with enhanced EGFR signaling with bortezomib, cetuximab, and radio-
therapy for head and neck cancer. Clin Cancer Res 2011;17:5755–5764.
24. Ahsan A, Hiniker SM, Ramanand SG, et al. Role of epidermal growth fac-
tor receptor degradation in cisplatin-induced cytotoxicity in head and neck
cancer. Cancer Res 2010;70:2862–2869.
25. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, Nyati MK. Role of cell
cycle in epidermal growth factor receptor inhibitor-mediated radiosensiti-
zation. Cancer Res 2009;69:5108–5114.
26. Feng FY, Varambally S, Tomlins SA, et al. Role of epidermal growth fac-
tor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene
2007;26:3431–3439.
27. Weihua Z, Tsan R, Huang WC, et al. Survival of cancer cells is maintained
by EGFR independent of its kinase activity. Cancer Cell 2008;13:385–393.
28. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dyspha-
gia and aspiration after chemoradiation for head and neck cancer. J Clin
Oncol 2006;24:2636–2643.
29. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swal-
lowing dysfunction and aspiration after radiation concurrent with chemo-
therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:
23–28.
30. Nyati MK, Feng FY, Maheshwari D, et al. Ataxia telangiectasia mutated
down-regulates phospho-extracellular signal-regulated kinase 1/2 via acti-
vation of MKP-1 in response to radiation. Cancer Res 2006;66:
11554–11559.
31. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein-
kinase activity, is related to p21. Cell 1994;78:67–74.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for
locoregionally advanced head and neck cancer: 5-year survival data from a
phase 3 randomised trial, and relation between cetuximab-induced rash
and survival. Lancet Oncol 2010;11:21–28.
TUMOR AND NORMAL MUCOSA BIOMARKERS MODULATION BY ERLOTINIB IN ORAL CANCER
HEAD &NECK—DOI 10.1002/HED SEPTEMBER 2013 1329
33. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radio-
therapy and chemotherapy for high-risk squamous-cell carcinoma of the
head and neck. N Engl J Med 2004;350:1937–1944.
34. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced
EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity.
Radiother Oncol 2005;76:157–161.
35. Ang KK, Zhang QE, Rosenthal DI. A randomized phase III trial (RTOG
0522) of concurrent accelerated radiation plus cisplatin with or without
cetuximab for stage III–IV head and neck squamous cell carcinomas
(HNC). J Clin Oncol 2011;29(Suppl):Abstract 5500.
36. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resist-
ance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;
27:3944–3956.
37. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treat-
ment with erlotinib in nonmetastatic head and neck squamous cell carci-
noma. Clin Cancer Res 2007;13:7086–7092.
38. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmaco-
dynamic biomarker studies in tumor and skin tissue samples of patients
with recurrent or metastatic squamous cell carcinoma of the head and
neck treated with erlotinib. J Clin Oncol 2007;25:2184–2190.
39. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor recep-
tor expression in pretreatment biopsies from head and neck squamous cell
carcinoma as a predictive factor for a benefit from accelerated radiation
therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560–5567.
40. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmaco-
dynamic biomarker studies in tumor and skin tissue samples of patients
with recurrent or metastatic squamous cell carcinoma of the head and
neck treated with erlotinib. J Clin Oncol 2007;25:2184–2190.
41. Van Waes C, Allen CT, Citrin D, et al. Molecular and clinical responses
in a pilot study of gefitinib with paclitaxel and radiation in locally
advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:
447–454.
TSIEN ET AL.
1330 HEAD &NECK—DOI 10.1002/HED SEPTEMBER 2013
